CellSource Co

CellSource Co Receivables/Revenue

The Receivables to Revenue Ratio of CellSource Co (4880.T) as of Nov 1, 2026 is 8.96 %. In the previous year, Receivables to Revenue Ratio was 7.43 % — a change of 20.66% (higher).

Receivables/Revenue

8.96 %

YoY

20.66%

Last updated:

Receivables to Revenue Ratio of CellSource Co is 2025 8.96 % . Receivables to Revenue Ratio of CellSource Co was 2024 7.43 % . It decreases by 20.66% higher compared to the previous year.

The CellSource Co Receivables/Revenue history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Receivables/Revenue
Date
Receivables/Revenue
Jan 1, 2018
11.26 JPY
Jan 1, 2019
8.33 JPY
Jan 1, 2020
12.12 JPY
Jan 1, 2021
10.52 JPY
Jan 1, 2022
15.20 JPY
Jan 1, 2023
8.01 JPY
Jan 1, 2024
7.43 JPY
Jan 1, 2025
8.96 JPY
The CellSource Co Receivables/Revenue history
YEARReceivables/RevenueYoY
8.96 %+20.66%
7.43 %-7.31%
8.01 %-47.29%
15.20 %+44.52%
10.52 %-13.21%
12.12 %+45.60%
8.33 %-26.08%
11.26 %+17.15%
9.61 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

CellSource Co Stock analysis

What does CellSource Co do? CellSource Co., Ltd. generates revenue through its Regenerative Medicine Related business segment, which provides contracted services for processing tissues and cells from fat and blood to medical institutions, along with support services for regenerative medicine laws and regulations related to safety assurance. The company also sells medical equipment within this segment. The Consumer business segment focuses on selling cosmetics and facial products directly to general consumers. Both segments operate under the company's brand without additional brand names mentioned in the description. The Regenerative Medicine Related business segment targets medical institutions and regulatory compliance support for regenerative medicine safety, while the Consumer business segment serves general consumers seeking cosmetics and facial care products. The company's products include processed tissue and cell services, regulatory support, medical equipment, and consumer skincare items, all sold under the CellSource brand. CellSource Co., Ltd. employs 109 full-time employees to manage its two business segments, with the Regenerative Medicine Related segment handling medical services and equipment sales, and the Consumer segment focusing on direct-to-consumer product sales. The company's revenue streams are derived from these two distinct operational areas without any additional external partnerships or third-party brands. CellSource Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about CellSource Co stock

Receivables to Revenue Ratio of CellSource Co is 8.96 % in 2025.

Receivables to Revenue Ratio of CellSource Co changed from 7.43 % to 8.96 %, representing a 20.66% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Receivables to Revenue Ratio CellSource Co since 2006 – with annual values, charts, and detailed analysis.

The Receivables/Revenue ratio shows what percentage of annual revenue is tied up in accounts receivable. Rising ratios may signal collection issues.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Receivables to Revenue Ratio's CellSource Co with sector peers and the industry average to assess whether it is attractive.

To evaluate Receivables to Revenue Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Receivables to Revenue Ratio.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — CellSource Co

All Key Metrics — CellSource Co